Stock price when the opinion was issued
They've been hit by a lot of input costs, which may be easing now. It's hard to raise prices on tissue paper and costs have been rising on recycled fibre. Their new container board factory will operate soon. CAS is selling at the low end of its range historically. But be patient until the stock price doubles or even triples.
(Analysts’ price target is $9.83)
Likes it, though shares have been down the past year. They fixed their operational issues. Demand remains strong in container board, and they opened a facility in Virginia which could raise margins. They sold their European division, so are more streamlined in operations. Pays around a 4% dividend. Still likes it.
Had a big miss last quarter, largely on the back of their tissue exposure, so this is a pretty opportune time to be buying. The free cash flow is in the neighbourhood of 15%. If there was an upswing in the tissue space, this would benefit, but is not something he is holding his breath for.